Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, October 22, 2026

Back to today

From X

@convequity 3 clicks

Convequity on X

$CRWV 5-year CDS hit a record ~1,195bp on 15 Oct and the whole neocloud group sold off with it. Our ABBX tracker suggests the market is pricing contagion into the wrong names. The balance sheet first. At 30 June CoreWeave had $35.6B of debt against $5.5B of cash, and its ~$33B market cap now sits below its debt. $4.4B falls due in the rest of 2026 and $6.2B in 2027, mostly loan amortisation; no bond matures before 2030. Its 9.625% notes sold at par in June now yield ~14.9%. Add $16.3B of lease liabilities and $35.5B of leases not yet started. CoreWeave's Q2 operating cash flow: Net loss: −$0.63B + Depreciation & amortisation: +$1.39B + Stock-based comp: +$0.17B + Other non-cash items: +$0.28B − Working capital (payables, receivables, prepaids): −$1.32B + Customer prepayments: +$0.79B = Operating cash flow: $0.68B The core business makes cash, but working capital ate it. Without the prepayments OCF was −$0.11B. That OCF is already after ~$0.44B of cash interest, equal to 65% of it, and capex ran 9.5x OCF. Funding is where the group splits. CoreWeave builds with borrowed money: GPU-backed loans, 8.5–9.75% bonds and vendor credit, with ~$9.8B of H1 equipment supplier-financed outside the cash-flow statement. Prepayments covered 12% of its Q2 capex. $NBIS builds with convertibles (~$9B this year) and prepayments that covered 21% of Q2 capex; at 30 June it held $8.5B of debt against $8.0B of cash. $IREN builds with equity, a $3B 1% convertible and prepayments that covered 87% of its latest quarter's capex; net debt is ~$1.7B and cash interest equalled ~1% of OCF. The exposure that matters is its landlords. CoreWeave is ~77% of $CORZ revenue, the tenant at Galaxy's Helios campus and leases 400MW from $APLD. Yet since 2 Oct Core Scientific is down 17%, while Microsoft-anchored IREN is down 34% and Nebius 30%. Our view: the risk is CoreWeave's debt-funded build, not the neocloud model. If CoreWeave stumbles, the hit lands on the landlords that depend on its rent. Nebius and IREN share the model, not the funding.
@StableBread 1 click

Fajasy on X

Between July 10 and August 20, Boost Run’s $BRUN float more than tripled, a problem the larger GPU clouds didn’t have. When I wrote my June 3 update, its float was only ~17.5M shares (12.65M public shares plus 10% of insider and sponsor shares that were never locked up). In my May 17 post, I expected most insider and sponsor shares to stay locked up until mid-November, based on an S-4 (merger filing) sentence that read as if only 10% could be released early. But the July 2 S-1 (its resale registration filing) shows the lockup ended for all of those shares once the stock closed at or above $12.00 on 20 of 30 trading days after the closing, which by my count happened on June 8, 2026. The resale registration for 58.7M shares then went effective on July 10, and after $BRUN called its warrants on July 21, exercises added 11.45M new shares by August 20. That took $BRUN’s float from ~17.5M shares to all 54.3M Class A shares, ~3.1x as many, between July 10 and August 20, while the stock fell from $28.44 to $19.40. So I’d blame the drop from $39.20 on two causes that have nothing to do with $BRUN’s core operations: (1) higher rates and borrowing costs, and (2) $BRUN’s float growing ~3.1x, which was expected once its lockup ended and its warrants were called.
@ACapitalLP

A Capital on X

This is a gift. $MSOS isn’t really a company, and while technically an ETF holding a basket of cannabis operators, I don’t even think of it as an index of companies. It’s a publicly traded proxy for US cannabis regulatory reform, trading near its lows. At $3.81, buying the equity is effectively buying a “perpetual regulatory option” with no fixed expiration date on any meaningful movement toward Schedule III rescheduling, banking reform, or broader federal legalization… Just the cost of waiting for Washington to do something…

Investor Letters

All letters

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.5B
Latticework by MOI Global 15 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.5B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $110M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $16M
Atrium Research - Equity Research 3 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 4 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $110M
Value Investors Club

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as…

VICR $9.7B
CV's Substack 28 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M
Calvin Blissett 10 clicks

Monte Investments Market Brief Vol. CXXXII

CoreWeave and neocloud peers face financing pressure, but sold-out GPU capacity and rising H100 and B200 rental rates support continued AI…

MYRG $4B
Monte Independent Investment Research 8 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 54 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.